The optimal treatment sequence of combined anti-CTLA4 and anti-PD1 (anti-CTLA4/PD1) inhibitors and BRAF/MEKi in patients with BRAF mutant advanced melanoma was recently investigated in the prospective randomized clinical trials DREAMseq and SECOMBIT; the latter included an additional arm investigating the planned switch to anti-CTLA4/PD1 inhibitors after an 8-week short course of BRAF/MEKi [16,17,18]. The gene discussed is BRAF; the disease is melanoma.